News

Gemcitabine, Carboplatin, and Bevacizumab Extend PFS

(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients with platinum-sensitive recurrent ovarian, peritoneal, or tubal cancer. The results, which were published... 

Webinar Highlights Research News from ASCO

On Monday, June 16, 2014, Dr. Douglas Levine of Memorial Sloan Kettering Cancer Center presented a free webinar focusing on research  news that was presented at 2014′s medical meetings.  In his hour-long presentation, he focused primarily on new ovarian cancer research that was presented at the... 

ASCO News: Two New Drugs Show Promise for Recurrent Ovarian Cancer

(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone. For this...